Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChina Pacific Regulatory News (CPIC)

Share Price Information for China Pacific (CPIC)

Share Price is delayed by 15 minutes
Get Live Data
26.60    0.00 (0.00%)
Bid:
22.60
Ask:
23.60
Spread: 1.00 (4.425%)
Market Cap: $51.18b
CPIC Live PriceLast checked at - London Stock Exchange

Intraday China Pacific Share Chart

  • This share is an international stock.

Stabilisation Notice

1 Jul 2020 07:00

RNS Number : 6143R
UBS AG London Branch
01 July 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

 

01 July 2020

 

China Pacific Insurance (Group) Co., LTD.

Mid-stabilisation Period Notice 

 

Further to the pre-stabilisation period announcement dated 16 June 2020, UBS AG London Branch (Contact: Francois-Olivier Mercier, Syndicate Desk: +44 20756 87504) hereby gives notice that stabilisation (within the meaning of Commission Delegated Regulation (EU) 2016/1052 supplementing the Market Abuse Regulation (EU) 596/2014) in relation to the offer of the following securities undertook by it or any of its affiliates in accordance with the rules of the Financial Conduct Authority.

 

The securities:

Issuer:

China Pacific Insurance (Group) Co., LTD.

Securities:

Global Depositary Receipts ("GDRs") each representing 5 A shares of the Company

ISIN:

US16951T1198

Offering size:

Institutional Offering: 102,873,300 GDRs (excluding the over-allotment option)

Market:

London Stock Exchange plc, Shanghai-London Stock Connect segment

Ticker:

CPIC

Description:

Initial Public Offering of GDRs

Offer price:

US$ 17.60 per GDR

Associated securities:

There are no associated instruments that are subject to stabilisation

Stabilising Manager:

UBS AG London Branch, 5 Broadgate, London. EC2M 2QS 

 

For each of the dates during which stabilisation transactions were carried out, the price range was as follows:

 

Trade Date

Lowest price (US$)

Highest price (US$)

Trading Venue

29/06/2020

17.60

17.60

LSE

 

 

Important legal information

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada, Japan, South Africa or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement is not an offer to sell, or solicitation of an offer to buy, acquire or subscribe for any securities to any person in the United States (including its territories and possessions, any state of the United States and the District of Columbia) or in any other jurisdiction in which such offer or solicitation would be unlawful. The GDRs have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any State or other jurisdiction of the United States and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable state or local securities law. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements.

In any member state of the European Economic Area (the "EEA") (each, a "Relevant Member State"), this announcement and the Offering are only addressed to and directed at persons who are "qualified investors" ("Qualified Investors") within the meaning of the Regulation (EU) 2017/1129 (the "Prospectus Regulation").

In the United Kingdom, this announcement and any offer if made subsequently is only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons"). This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors and other persons who are permitted to subscribe for the GDRs described herein pursuant to an exemption from the Prospectus Regulation and other applicable legislation, and will only be engaged in with such persons.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STAFMMRTMTJJBLM
Date   Source Headline
28th Apr 202510:43 amRNSApproval of Director's Appointment Qualification
25th Apr 202510:53 amRNSSummaries of the Quarterly Solvency Reports
25th Apr 202510:51 amRNS2025 First Quarter Report
22nd Apr 202512:00 pmRNS2024 Sustainability Report
11th Apr 202511:36 amRNSAnnouncement relating to Premium Income
7th Apr 202510:21 amRNSResignation of Director of the Board
26th Mar 202512:00 pmRNSPublication of Summaries of Solvency Reports
26th Mar 202511:31 amRNSPublication of Annual Results Presentation
26th Mar 202511:14 amRNSCPIC 2024 Annual Report
21st Mar 202510:46 amRNSChange of Chairman of a Subsidiary
21st Mar 202510:43 amRNSResignation of Chairman of a Subsidiary
18th Mar 20259:44 amRNSConvening of 2024 Annual Results Presentation
14th Mar 202510:07 amRNSAnnouncement relating to Premium Income
18th Feb 20259:36 amRNSAnnouncement relating to Premium Income
24th Jan 202510:04 amRNSAnn on Approval of Appointment Qualifications
22nd Jan 202510:36 amRNSAnn on Estimated Increase in 2024 Annual Earnings
16th Jan 20259:22 amRNSAnnouncement relating to Premium Income
27th Dec 202410:50 amRNSApproval of Appointment Qualification
13th Dec 20248:46 amRNSPDMR Shareholding
11th Dec 20249:17 amRNSAnnouncement relating to Premium Income
14th Nov 20248:53 amRNSAnnouncement relating to Premium Income
30th Oct 20249:28 amRNSPublication of Summaries of Solvency Reports
30th Oct 20249:23 amRNSAdjustment to the Composition of Special Committee
30th Oct 20249:19 amRNSAppointment of Chairman and Vice Chairwoman of BOS
30th Oct 20249:19 amRNSAppointment of VP and Change of CFO
30th Oct 20249:04 amRNS2024 Third Quarter Report
21st Oct 202410:17 amRNS2024 Q3 Results Presentation
16th Oct 202410:40 amRNSAnnouncement relating to Premium Income
15th Oct 202410:32 amRNSEstimated Increase for the First Three Quarters
14th Oct 202411:58 amRNSAnnouncement on Poll Results for the EGM
30th Sep 20249:37 amRNSAnnouncement on approval of AoA by NFRA
30th Sep 20249:36 amRNSApproval of Directors’ Appointment Qualifications
20th Sep 202410:37 amRNSNotice of the EGM
20th Sep 202410:31 amRNSApproval of Supervisors' Appointment Qualification
13th Sep 202410:06 amRNSPDMR Shareholding
11th Sep 20249:45 amRNSAnnouncement relating to Premium Income
10th Sep 20247:48 amRNSPDMR Shareholding
29th Aug 20241:17 pmRNSPublication of Summaries of Solvency Reports
29th Aug 20241:11 pmRNSPublication of 2024 Interim Results Presentation
29th Aug 20241:03 pmRNSCPIC 2024 Interim Report
29th Aug 202412:08 pmRNSResignation of Director of the Board
28th Aug 202410:33 amRNSResignation of Chairwoman of a Subsidiary
21st Aug 202410:12 amRNSConvening of 2024 Interim Results Presentation
13th Aug 202410:26 amRNSAnnouncement relating to Premium Income
25th Jul 20247:00 amRNSDirector Shareholding
16th Jul 202410:38 amRNSAnnouncement relating to Premium Income
11th Jun 202410:23 amRNSAnnouncement relating to Premium Income
6th Jun 202411:31 amRNSResult of 2023 AGM
3rd Jun 202410:29 amRNSPDMR Shareholding
28th May 202410:47 amRNSElection of Employee Representative Supervisors

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.